NRIX is trading 4.1% up at $24.82 as investors continue to bid the stock higher following its high-value collaboration with Roche.

  • Under the global deal, Roche will pay a $700 million upfront fee and up to $2.3 billion in total potential milestones to co-develop and co-commercialize the BTK degrader bexobrutide.
  • The market appears to still be repricing the stock as investors digest the significant financial scale and long-term implications of the partnership news.